tert-Butyl (2-((2-aminoquinolin-4-yl)oxy)ethyl)carbamate, 95.0%, 250mg

Benzo[c]isothiazole-4-carboxylic acid, 95.0%, 1g

Benzyl 2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride, 98%, 100mg

tert-butyl (3S,4R)-3-(hydroxymethyl)-4-[2-(trifluoromethyl)phenyl]pyrrolidine-1-carboxylate, 100mg

Ethyl 4-amino-2-nitrobenzoate, 95.0%, 5g

[(5-Bromopentyl)oxy](tert-butyl)dimethylsilane, 95%, 100mg

2-(Trifluoromethyl)cinnamic acid, 95.0%, 10g

4-(2-Methyl-1H-imidazol-1-yl)benzoic acid, >95%, 25g

Microliter syringe GASTIGHT® series 1700 Point type 2, 100 µl, 1710 RN, 1 piece

Ethyl 5-amino-1-(2-hydroxyethyl)-1H-pyrazole-4-carboxylate, 95.0%, 1g

tert-Butyl N-tert-butoxycarbonyl-N-(7H-purin-6-yl)carbamate, 95.0%, 25g

7-(1-naphthyl)-7-oxoheptanoic acid, 97.0%, 1g

(E)-3-(4-Nitrophenyl)acrylaldehyde, 97%, 1g